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Abstract
Introduction This trial evaluated the safety, biologic activity, and
pharmacokinetics of belimumab, a fully human monoclonal
antibody that inhibits the biologic activity of the soluble form of
the essential B-cell survival factor B-lymphocyte stimulator
(BLyS) in patients with systemic lupus erythematosus (SLE).
Methods Seventy patients with mild-to-moderate SLE were
enrolled in a phase I, double-blind, randomized study and
treated with placebo (n = 13) or belimumab (n = 57) at four
different doses (1.0, 4.0, 10, and 20 mg/kg) as a single infusion
or two infusions 21 days apart. Patients were followed for 84 to
105 days to assess adverse events, pharmacokinetics,
peripheral blood B-cell counts, serology, and SLE disease
activity. Data from the study were summarized using descriptive
statistics. χ2 type tests were used to analyze discrete variables.
The Kruskal-Wallis test, the Wilcoxon test, and the analysis of
covariance were used to analyze the continuous variables, as
appropriate. The analysis was performed on all randomized
patients who received study agent.
Results The incidences of adverse events and laboratory
abnormalities were similar among the belimumab and placebo
groups. Belimumab pharmacokinetics were linear across the 1.0
to 20 mg/kg dose range. Long terminal elimination half-life (8.5
to 14.1 days), slow clearance (7 ml/day per kg), and small
volume of distribution (69 to 112 ml/kg) were consistent with a
fully human antibody. Significant reductions in median
percentages of CD20+ B cells were observed in patients treated
with a single dose of belimumab versus placebo (day 42: P =
0.0042; and day 84: P = 0.0036) and in patients treated with
two doses of belimumab versus placebo (day 105: P = 0.0305).
SLE disease activity did not change after one or two doses of
belimumab.
AE: adverse event; ANA: anti-nuclear antibody; ANC: absolute neutrophil count; BlyS: B-lymphocyte stimulator; dsDNA: double-stranded DNA; 
ELISA: enzyme-linked immunosorbent assay; HAHA: human anti-human antibody; mAb: monoclonal antibody; PGA: Physician's Global Disease 
Assessment; SELENA: Safety of Estrogens in Lupus Erythematosus National Assessment; SF-36: 36-item Short Form; SLE: systemic lupus ery-
thematosus; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; TNF: tumor necrosis factor.Arthritis Research & Therapy    Vol 10 No 5    Furie et al.
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Conclusions Belimumab was well tolerated and reduced
peripheral B-cell levels in SLE patients. These data support
further studies of belimumab in autoimmune disorders.
Trial Registration NCT00657007 [clinicaltrials.gov].
Introduction
Systemic lupus erythematosus (SLE) is typified by the produc-
tion of autoantibodies, such as anti-double-stranded DNA
(anti-dsDNA) antibodies and anti-nuclear antibodies (ANAs).
Although the disease is characterized by the presence of auto-
reactive T lymphocytes, there is growing  evidence that B cells
play a central role in the pathogenesis of SLE [1-3]. Hyperac-
tive B cells may mediate disease by promoting the expansion
of autoreactive CD4+ T cells via antigen presentation [1-3].
The frequency of circulating plasma cells correlates with SLE
disease activity and with the titer of anti-dsDNA autoantibod-
ies [4]. Therefore, B-cell and plasma cell depletion may be an
appropriate therapeutic approach in the treatment of SLE.
B-lymphocyte stimulator (BLyS) is a member of the tumor
necrosis factor (TNF) ligand superfamily of cytokines that is
expressed and secreted by monocytes, macrophages, den-
dritic cells, and granulocyte colony-stimulating factor activated
neutrophils [5,6]. BLyS exists in both membrane-bound and
soluble forms. The biologically active, soluble form of BLyS is
enzymatically cleaved from the cell membrane and can bind to
any of three receptors: TACI (transmembrane activator and
calcium-modulator and cyclophilin ligand interactor) [7];
BCMA (B-cell Maturation Antigen) [8]; and BAFF-R (B-cell
lymphocyte activating factor receptor)/BLyS receptor 3
[9,10], localized primarily on B lymphocytes. BLyS contributes
to B-cell proliferation and differentiation, and it is important in
immunoglobulin class switching [5,11]. Constitutive over-
expression of BLyS in transgenic mice results in the develop-
ment of an autoimmune-like disease that is characterized by
hypergammaglobulinemia, autoantibody production, and
glomerulonephritis [8,12,13]. In murine lupus, treatment with a
BLyS antagonist significantly reduces the occurrence of pro-
teinuria and prolongs survival [8,14]. Moreover, elevated BLyS
blood levels have been found in some patients with SLE
[15,16], and observational studies demonstrated that BLyS
concentrations change over time in the majority of SLE
patients [17,18]. Increases in BLyS levels correlated with
increased disease activity and were predictive of future dis-
ease activity, suggesting that BLyS may be a biomarker for
SLE [17].
Belimumab (LymphoStat-B; Human Genome Sciences, Inc.,
Rockville, MA, USA) is a recombinant, fully human, IgG1λ mAb
that binds to soluble BLyS with high affinity. The antibody
exerts its biologic activity by preventing the binding of BLyS to
its receptors [19]. Belimumab potently inhibits BLyS-induced
proliferation of B cells in vitro and prevents human BLyS-
induced increases in splenic B-cell numbers and serum IgA tit-
ers in mice [19]. In cynomolgus monkeys treated with belimu-
mab, reductions as great as 75% were observed in the
number of lymphoid tissue and peripheral blood CD20+ B
cells and CD21+ plasmacytoid cells [20]. Importantly, intrave-
nous doses of up to 50 mg/kg delivered every 2 weeks over 6
months were well tolerated in cynomolgus monkeys. On dis-
continuation of belimumab in cynomolgus monkeys, the num-
bers of peripheral blood CD20+ B cells recovered to normal
levels within 3 to 5 months [20]. Because belimumab has the
potential to provide therapeutic benefit in SLE patients, we
conducted a phase I study of belimumab in SLE patients with
stable, mild to moderate disease activity and demonstrated its
safety, biologic activity, and pharmacokinetics.
Materials and methods
Patients
Patients aged 18 years or older with SLE, as defined by the
American College of Rheumatology criteria [21], were
enrolled in the trial. Eligible patients had stable SLE disease
activity, as clinically judged by the principal investigator, for at
least 2 months before screening and were either maintained
with no medication or with a stable treatment regimen of low-
dose (≤ 15 mg) prednisone, antimalarials, nonsteroidal anti-
inflammatory drugs, methotrexate, azathioprine, or mycophe-
nolate mofetil. Patients were required to have a history of
measurable anti-dsDNA, anti-Smith, anti-ribonucleoprotein,
anti-cardiolipin, anti-Sjögren's syndrome-A/Ro,  or anti-Sjög-
ren's syndrome-B/La autoantibodies. Patients with active
lupus nephritis requiring hemodialysis, cyclophosphamide, or
high-dose (>60 mg) prednisone, or who had received lefluno-
mide, cyclosporin, intravenous gammaglobulin, or plasmapher-
esis within 6 months of screening were not eligible. Patients
with active central nervous system lupus within 6 months of
screening, a history of renal transplant, hypogammaglobuline-
mia or IgA deficiency, evidence of clinically significant non-
SLE-related acute or chronic disease, or a history of any seri-
ous infection within 4 weeks of study entry were also excluded.
Pregnant or nursing patients were ineligible for inclusion in the
study, and adequate contraceptives were required in partici-
pating patients. The protocol was approved by each center's
institutional review board, and all patients provided written
informed consent.
Study design and treatment
This was a phase I, multicenter (20 sites), randomized, double-
blind, placebo-controlled, dose-escalation study of belimumab
in patients with SLE. Patients received belimumab 1.0, 4.0,
10, or 20 mg/kg or placebo administered intravenously over at
least 2 hours. Patients in cohorts 1 to 4 received a single doseAvailable online http://arthritis-research.com/content/10/5/R109
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of belimumab or placebo, whereas patients in cohorts 5 to 8
received two identical doses of belimumab or placebo 3
weeks apart.
Permission to escalate the dose was granted by the Human
Genome Sciences Review Committee. The primary safety
end-point for dose escalation was the incidence of grade 3
(severe) or 4 (life-threatening) adverse events (AEs). Dose
escalation and initial dosing of the double-dose cohorts were
not allowed if two or more patients in a cohort experienced a
grade 3 or 4 AE, including hypogammaglobulinemia.
Safety assessment
AEs were coded on the basis of the Medical Dictionary for
Regulatory Activities terminology version 6.0 and were graded
for severity according to the National Institutes of Health Divi-
sion of Microbiology and Infectious Diseases Adult Toxicity
Tables (Version May 2001). Adverse events and serious AEs
were considered treatment emergent if they occurred within
84 days after the final dose of study agent (day 84 for single-
dose cohorts and day 105 for double-dose cohorts). Hematol-
ogy, clinical chemistry, and urinalysis panels were assessed on
days 0, 2, 7, 14, 28, 42, 56, and 84 for patients in the single-
dose cohorts, and on days 0, 2, 7, 14, 21, 23, 28, 35, 49, 63,
77, and 105 for patients in the double-dose cohorts. In a 4-
week, preclinical monkey toxicology study, one (asympto-
matic) animal treated with high dose belimumab (50 mg/kg)
was found at terminal necropsy to have multiple splenic
abscesses that might have existed before treatment. There-
fore, abdominal computed tomography scans with oral con-
trast were performed randomly in half of the patients in each
cohort at screening and 28 days after the last dose to evaluate
the risk for abdominal infection. It should be noted that in a
subsequent 26-week, multiple-dose (0 to 50 mg/kg) monkey
toxicology study, belimumab was well tolerated and no
abscesses or other toxicities were identified [20].
Immunogenicity assessment
Blood samples were evaluated for anti-belimumab antibodies
on day 0 before dosing and on days 14, 28, 56, and 84 for
patients in single-dose cohorts; samples were obtained in the
double-dose cohorts on days 0 and 21 before dosing and on
days 14, 35, 49, 77, and 105. Samples were allowed to clot
for 30 minutes at room temperature, centrifuged at 1,000 to
1,300 g for 10 to 15 minutes, and the serum was decanted
and immediately frozen. The presence of anti-belimumab anti-
bodies was determined using two screening ELISAs. The first
assay was performed using the Fab portion of belimumab
immobilized to a microtiter plate. Captured anti-belimumab
antibodies were detected with horseradish peroxidase-conju-
gated goat anti-human IgG+IgA+IgM antibody and were
quantitated by color conversion of tetramethylbenzidine. The
second assay was performed using belimumab (whole anti-
body) immobilized to a microtiter plate. Captured anti-belimu-
mab antibodies were detected with horseradish peroxidase-
conjugated goat anti-human κ chain specific antibody, and
they were quantitated by color conversion of tetramethylbenzi-
dine. A serum sample was considered potentially positive for
anti-belimumab if the mean A450 value of the postdose sample
was at least twofold greater than the mean A450 value of the
predose sample.
Samples that had tested positive in either screening assay
were then examined in a neutralization assay. Predose and
postdose samples were serially diluted and added to micro-
plates coated with immobilized belimumab, followed by the
addition of europium-labeled BLyS. Anti-belimumab antibody
present in the sample would bind to the immobilized belimu-
mab, and competitively inhibit binding of europium-labeled
BLyS. Europium-labeled BLyS binding was quantitated by
time-resolved fluorometric spectroscopy at 615 nm (excitation
at 340 nm). A sample was considered to contain neutralizing
anti-belimumab antibody if the mean postdose signal was sta-
tistically lower than the mean predose signal (P  < 0.01,
unpaired one-tailed t-test).
Systemic lupus erythematosus disease activity 
assessment
Primary outcomes for clinical disease activity included the
Safety of Estrogens in Lupus Erythematosus National Assess-
ment (SELENA) Systemic Lupus Erythematosus Disease
Activity Index (SLEDAI) [22], Flare Index [22,23], and the Phy-
sician's Global Disease Assessment (PGA). Proper use of
these instruments was reviewed at the investigator's meeting.
The PGA was based on a visual analog scale ranging from 0
(no disease activity) to 3 (severe disease activity). The Short
Form-36 (SF-36; version 2) Health Survey, a self-administered
survey, was incorporated to assess quality of life. All clinical
disease activity measurements were assessed on days 0, 28,
56, and 84 for patients in the single-dose cohorts, and on days
0, 21, 49, 77, and 105 for patients in the double-dose cohorts.
Pharmacokinetics
Serum concentrations of belimumab were determined by
ELISA. BLyS-reactive belimumab was captured from diluted
human serum onto BLyS-coated microtiter plates. Captured
belimumab was detected using peroxidase-conjugated sec-
ondary mouse monoclonal anti-human IgG antibody. The
lower limit of quantitation for this ELISA assay is 138.5 ng/mL
of belimumab in 100% human serum.
Biologic marker assessment
Biologic marker assessments included CD20+ B cells and
CD138+ plasmacytoid cells, anti-dsDNA antibodies, ANAs,
immunoglobulins (IgG, IgM, IgE, and IgA), and complement
(C3 and C4). Anti-dsDNA antibodies and ANAs were meas-
ured by Farr assay (Specialty Laboratories, Santa Monica, CA,
USA) and indirect fluorescent antibody assay (FOCUS Diag-
nostics, Herndon, VA, USA), respectively. Immunoglobulins,
C3, and C4 were measured by nephelometry (FOCUSArthritis Research & Therapy    Vol 10 No 5    Furie et al.
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Diagnostics). Blood samples were drawn at screening (day 0)
and on days 14, 28, 42, 56, and 84 for patients in single-dose
cohorts, and at screening and on days 0, 14, 21, 35, 49, 63,
77, and 105 for patients in double-dose cohorts. Absolute
counts of B cells and plasmacytoid cells were calculated on
the basis of white blood cell counts multiplied by the percent-
age of lymphocytes and the percentage of cells staining for the
CD20 and CD138 markers, respectively, as determined by flu-
orescence-activated flow cytometry. BLyS levels could not be
measured because the presence of belimumab in the blood
interfered with the detection of BLyS.
Statistical methods
Data from the study were summarized using descriptive statis-
tics. χ2 type tests were used to analyze discrete variables. For
continuous variables, the Kruskal-Wallis test was used to
examine the difference across all treatment groups, and the
Wilcoxon test was used to compare the differences between
placebo and each of the belimumab-treated groups. An analy-
sis of covariance was used to analyze the continuous variables
if there was a significant difference in the variable at baseline.
The analysis was performed on a modified intent-to-treat pop-
ulation, defined as the subset of all randomized patients who
received study agent. All statistical analyses were performed
using SAS (SAS Institute Inc., Cary, NC, USA), WinNonlin
(Pharsight Corp., Mountain View, CA, USA), or R statistical
packages.
Results
Patients
A total of 70 patients were enrolled in this study (Table 1). The
majority (91%) of patients were female, and the median age
was 38.5 years (range 22 to 80 years). Half of the patients
were white, and 47% of patients were African American; all
treatment groups included patients of Hispanic origin. The
median duration of disease was 6.5 years (range 0.3 to 37.7
years). The majority of patients had disease manifestations
that included ANA positivity (97%), immunologic disorder
(89%), arthritis (87%), hematologic disorder (64%), or malar
rash (56%) at the time of diagnosis. At baseline, 90% of the
patients had ANA titers of 1:40 or greater, 60% were anti-
dsDNA antibody positive (≥ 5 IU/ml) with some variability in
median anti-dsDNA antibody levels (4.5 to 27.0 IU/ml) across
dose groups, and an average SELENA SLEDAI score of 2.2
(range 0 to 8 points). There were no significant differences
between treatment groups in terms of demographics, baseline
disease duration, serology, or manifestations. Eighty per cent
of patients were on an immunosuppressive agent, and there
were no significant differences in the distribution of patients
who were on mycophenolate, prednisone, or methotrexate
(Table 2). However, there were more patients in the placebo
group (38%) compared with the belimumab-treated group
(12%) who were on azathioprine (P = 0.04). Thirty-six patients
were randomly assigned to receive a single dose of study
agent and 34 to receive two doses 21 days apart. All patients
completed the study per protocol.
Safety
Overall, AEs were reported in 12 (92%) patients treated with
placebo and 55 (97%) patients treated with belimumab (Table
3). The majority of AEs were mild to moderate in severity, and
the incidence of AEs was similar in the placebo and belimu-
mab (single and double dose) treatment groups. There was no
increase in the incidence of infections in the belimumab
groups (37% for all patients treated with active agent versus
62% for placebo), and only one infection (tinea pedis) was
reported to be possibly related to study agent. The most com-
mon AEs in patients treated with belimumab were arthralgia
(26%), headache (21%), rash (21%), diarrhea (18%), and
nausea (18%). Although diarrhea and rash did not occur in the
13 patients who received placebo, these events were gener-
ally mild to moderate and were often felt to be unrelated to
study drug. Furthermore, dose-dependent trends in those
treated patients who developed diarrhea or rash were not
observed. The most common AEs in patients treated with pla-
cebo were arthralgia (31%), nausea (31%), upper respiratory
tract infection (15%), and joint swelling (15%). The frequency
of AEs did not change with increasing doses of belimumab.
Overall, there was no significant difference in the incidence of
specific AEs between the belimumab groups and placebo.
The majority of AEs were considered not related or probably
not related to study agent. In addition, there were no signifi-
cant differences between placebo-treated and belimumab-
treated groups in the incidence of grade 3 or 4 laboratory or
hematologic toxicities (Table 4). Frequencies of hematologic
or laboratory abnormalities did not vary with increasing dose or
number of doses of belimumab. There were three patients
(two in the 10 mg/kg double-dose cohort and one in the 4 mg/
kg single-dose cohort) who developed grade 3 neutropenia
(500 to 970/mm3 absolute neutrophil count [ANC]) at one or
two time points (days 14 or 63) during the study. The occur-
rences of neutropenia were not considered AEs because
repeat complete blood counts within 1 week showed ANC to
be returning to within the reference range or improving to mild
or grade 1 severity. The patient (10 mg/kg double dose) with
an ANC of 500/mm3 recovered and was rechallenged on day
23 without recurrence of neutropenia. Two patients in the sin-
gle-dose cohort (one 4 mg/kg and one 20 mg/kg) developed
grade 1 or 2 neutropenia considered AEs. The patients receiv-
ing 4 mg/kg belimumab sustained grade 2 neutropenia (1,160
to 1,460/mm3 ANC) on days 28 to 84. The patient receiving
20 mg/kg belimumab sustained grade 1 neutropenia (1,720 to
1,940/mm3 ANC) on days 56 and 84.
Abdominal computed tomography scans with oral contrast
revealed no evidence of infections or abdominal abscesses.
Two patients developed a human anti-human antibody
(HAHA) response. A single patient in the 20 mg/kg double-Available online http://arthritis-research.com/content/10/5/R109
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dose cohort (on concomitant mycophenolate mofetil and pred-
nisone) developed detectable, non-neutralizing HAHA only on
day 77. The other patient in the 1 mg/kg single dose cohort
(on concomitant prednisone) had detectable neutralizing
HAHA on days 14 to 56.
Ten patients (one placebo and nine belimumab) experienced
a grade 3 (severe) AE, and one patient (belimumab) experi-
enced a grade 4 (potentially life-threatening) AE of thrombocy-
topenia (Table 4), which was considered probably not related
to the study agent. Most events were considered not related
or probably not related to study agent. Grade 3 urticaria with
chest pain was reported in one patient with a prior history of
drug-induced urticaria during the administration of a 20 mg/kg
single dose. The infusion was discontinued approximately 40
minutes after initiation, and the urticaria and chest pain
resolved with two doses of intravenous diphenhydramine.
Six patients (one placebo and five belimumab) developed
eight serious AEs, none of which were considered related to
study agent. Patients in the belimumab single-dose cohorts
reported diarrhea, dehydration, and sinus headache (one
patient), staphylococcal cellulitis (one patient), and
angioedema (one patient). Patients in the belimumab double-
dose cohorts reported chest pain (one patient) and pancreati-
tis (one patient), whereas a patient in the placebo cohort
Table 1
Patient demographics and disease characteristics by treatment groups
Patient demographic or disease 
characteristic
Placebo (n = 13) Belimumab
1.0 mg/kg (n = 15) 4.0 mg/kg (n = 14) 10 mg/kg (n = 14) 20 mg/kg (n = 14) All active (n = 57)
Sex (n [%])
Female 11 (85) 15 (100) 13 (93) 12 (86) 13 (93) 53 (93)
Male 2 (15) 0 1 (7) 2 (14) 1 (7) 4 (7)
Race (n [%])
White 10 (77) 7 (47) 3 (21) 8 (57) 7 (50) 25 (44)
African American 3 (23) 8 (53) 11 (79) 5 (36) 6 (43) 30 (53)
Asian 0 0 0 1 (7) 1 (7) 2 (4)
Hispanic origin (n [%]) 4 (31) 2 (13) 1 (7) 5 (36) 1 (7) 9 (16)
Age (years; median [range]) 38 (30 to 58) 36 (22 to 56) 48.5 (23 to 62 37 (22 to 61) 38.5 (23 to 80) 39 (22 to 80)
Duration of SLE (years; median 
[range])
5.3 (0.4 to 15.3) 3.4 (0.4 to 13) 8.7 (0.4 to 37.7) 6.3 (1.8 to 20.8) 8.0 (0.3 to 29.4) 6.9 (0.3 to 37.7)
SELENA SLEDAI score (median 
[range])
4 (0 to 4) 2 (0 to 6) 0 (0 to 5) 2 (0 to 8) 2 (0 to 4) 2 (0 to 8)
ANA ≥1:40 at baseline (n [%]) 12 (92) 13 (87) 14 (86) 13 (93) 13 (93) 53 (93)
Anti-dsDNA antibody (IU/ml; 
median [range])
9.5 (4.0 to 162.5) 6.0 (4.0 to 65.5) 4.5 (4.0 to 24.0) 27.0 (4.0 to 257.0) 5.0 (4.0 to 729.0) 6.5 (4.0 to 729.0)
Manifestations at the time of SLE 
diagnosis (n [%])
Antinuclear antibody 13 (100) 14 (93) 14 (100) 14 (100) 13 (93) 55 (97)
Immunologic disorder 12 (92) 12 (80) 12 (86) 14 (100) 12 (86) 50 (88)
Arthritis 12 (92) 14 (93) 11 (79) 12 (86) 12 (86) 49 (86)
Hematologic disorder 7 (54) 14 (93) 9 (64) 7 (50) 8 (57) 38 (67)
Malar rash 6 (46) 8 (53) 5 (36) 12 (86) 8 (57) 33 (58)
Photosensitivity 7 (54) 7 (47) 6 (43) 9 (64) 8 (57) 30 (53)
Serositis 6 (46) 4 (27) 8 (57) 7 (50) 8 (57) 27 (47)
Oral ulcers 8 (62) 10 (67) 6 (43) 6 (43) 5 (36) 27 (47)
Renal disorder 4 (31) 2 (13) 4 (29) 6 (43) 4 (29) 16 (28)
Discoid rash 3 (23) 1 (7) 5 (36) 4 (29) 2 (14) 12 (21)
Neurologic disorder 0 3 (20) 1 (7) 1 (7) 1 (7) 6 (11)
ANA, antinuclear antibody; SLE, systemic lupus erythematosus; SELENA, Safety of Estrogens in Lupus Erythematosus National Assessment; SLEDAI, Systemic Lupus 
Erythematosus Disease Activity Index.Arthritis Research & Therapy    Vol 10 No 5    Furie et al.
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Table 2
Frequency of use of immunosuppressive agents during the study
Immunosuppressive drugs Placebo (n = 13) Belimumab
1.0 mg/kg (n = 15) 4.0 mg/kg (n = 14) 10 mg/kg (n = 14) 20 mg/kg (n = 14) All active (n = 57)
Prednisone 9 (69) 14 (93) 9 (54) 10 (71) 8 (57) 41 (72)
Methotrexate 2 (15) 1 (7) 0 2 (14) 3 (21) 6 (11)
Azathioprine 5 (38) 2 (13) 2 (13) 2 (14) 1 (7) 7 (12)
Mycophenolate 0 1 (7) 1 (7) 1 (7) 5 (36) 8 (14)
None 3 (23) 1 (7) 5 (36) 3 (21) 3 (21) 12 (21)
Table 3
Incidence (three or more patients) of adverse events by dose: single-dose and double-dose cohorts combined
Adverse event Placebo (n = 13) Belimumab
1.0 mg/kg (n = 15) 4.0 mg/kg (n = 14) 10 mg/kg (n = 14) 20 mg/kg (n = 14) All active (n = 57)
Arthralgia 4 (31) 3 (20) 2 (14) 7 (50) 3 (21) 15 (26)
Headache 1 (8) 3 (20) 3 (21) 4 (29) 2 (14) 12 (21)
Rash 0 4 (27) 2 (14) 2 (14) 4 (29) 12 (21)
Diarrhea 0 5 (33) 1 (7) 1 (7) 3 (21) 10 (18)
Nausea 4 (31) 2 (13) 3 (21) 2 (14) 3 (21) 10 (18)
Fatigue 0 1 (7) 2 (14) 3 (21) 1 (7) 7 (12)
Back pain 1 (8) 0 2 (14) 1 (7) 3 (21) 6 (11)
Joint swelling 2 (15) 0 1 (7) 0 4 (29) 5 (9)
Synovitis 1 (8) 2 (13) 0 3 (21) 0 5 (9)
Depression 0 3 (20) 0 0 0 3 (5)
Infections and infestations 8 (62) 4 (27) 8 (57) 4 (29) 5 (36) 21 (37)
Upper respiratory tract infection 2 (15) 0 3 (21) 1 (7) 3 (21) 7 (12)
Thrombocytopeniaa 0 0 1 (7) 0 0 1 (2)
Pancreatitisb 0 0 0 0 1 (7) 1 (2)
Cellulitis staphylococcalb 0 0 0 1 (7) 0 1(2)
Sepsisb 1  ( 8 ) 0 0 000
Aspartate aminotransferase 
increasedb
0 0 0 0 1 (7) 1 (2)
Blood creatinine increasedb 0 0 0 0 1 (7) 1 (2)
Neutrophil count decreasedb 0 002  ( 1 4 ) 0 2  ( 4 )
Dehydrationb 0 0 0 0 1 (7) 1 (2)
Pain in extremityb 0 0 1 (7) 0 0 1 (2)
Headacheb 0 0 0 1 (7) 0 1 (2)
Sinus headacheb 0 1  ( 7 ) 0 001  ( 2 )
Angioneurotic edemab 0 0 1 (7) 0 0 1 (2)
Urticariab 0 0 0 0 1 (7) 1 (2)
Values are expressed as n (%). aGrade 4 potentially life-threatening adverse event. bGrade 3 severe adverse eventAvailable online http://arthritis-research.com/content/10/5/R109
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developed sepsis (one patient). There was no significant dif-
ference in the incidence of severe or serious AEs between
patients treated with placebo and those treated with belimu-
mab. There were no deaths during the study.
Pharmacokinetics
Following intravenous administration, serum belimumab con-
centrations declined in a bi-exponential manner, with a mean
distribution phase half-life of 1.0 to 2.2 days and a mean termi-
nal elimination half-life of 8.5 to 14.1 days (Table 5 and Figure
1). Belimumab was distributed to tissues with a mean steady-
state volume of distribution ranging from 69 to 112 ml/kg, rep-
resenting approximately twice the mean initial volume of distri-
bution, which ranged from 40 to 57 ml/kg. The mean
clearance after a single intravenous dose was approximately 7
ml/day per kg for all four cohorts, which is much less than the
glomerular filtration rate, indicating that renal clearance is not
a major component of belimumab clearance. Drug accumula-
tion for maximum serum drug concentration averaged 9%
when two doses of 4.0, 10, or 20 mg/kg were administered 21
days apart, which was as expected on the basis of the mean
terminal elimination half-life of 9.6 to 14.1 days for those
cohorts. There were no significant differences in pharmacoki-
netic parameters between single-dose and double-dose
cohorts. Concomitant use of immunosuppressants, hydroxy-
chloroquine, and/or prednisone during the study had no signif-
icant effects on belimumab pharmacokinetics (data not
shown). Overall, belimumab pharmacokinetics were linear
across the 1.0 to 20 mg/kg dose range, except in the two
patients who developed anti-belimumab antibody responses.
In these patients, the observed belimumab serum concentra-
tions were 2-fold to 3.5-fold lower than the predicted values at
the time points when anti-belimumab antibodies were
detected.
Biologic activity
In general, the percentage reduction in CD20+ B cells was
greater in patients treated with belimumab than in those
treated with placebo (Figure 2). The median CD20+ B-cell
count and percentage of lymphocytes at baseline were similar
in the placebo (159 cells/ml and 13.5% [range 2% to 36%],
respectively) and belimumab (176 cells/ml and 13.5% [range
2% to 51%], respectively) treatment groups. Baseline CD20+
B-cell and CD138+ plasmacytoid cell count data were not
available for one patient in the 4.0 mg/kg single-dose belimu-
mab cohort. Compared with placebo, a significantly greater
reduction in median percentage of CD20+  B cells was
observed in the combined group of patients treated with either
a single dose of belimumab (day 42: P = 0.0042; and day 84:
P  = 0.0036) or two doses of belimumab (day 105: P  =
0.0305). The median reduction from baseline in CD20+ B cells
at day 84 for the single-dose cohorts ranged from 11% to
47%, whereas a 23% increase was observed in the placebo
group. In the double-dose cohorts, the median reduction in
CD20+ B cells at day 105 ranged from 27% to 43%, whereas
a 5% increase was observed in the placebo group. When
patients with baseline values of 5% CD20+ cells or greater
were pooled across all cohorts (n = 65), the overall treatment
effect was significant at 42, 56, and 84 days after the last dose
(P < 0.01 for each). Patients on belimumab and mycopheno-
late mofetil (n = 8) had statistically significant differences in
CD20+ B cells at some time points compared with those (n =
Table 4
Summary of grade 3 and 4 laboratory and hematologic toxicities
Parameter Grade Placebo (n = 13) Belimumab
1.0 mg/kg 
(n = 15)
4.0 mg/kg 
(n = 14)
10 mg/kg 
(n = 14)
20 mg/kg 
(n = 14)
All active 
(n = 57)
Activated partial 
thromboplastin time
3 0 0 1 (7) 0 1 (7) 2 (4)
Creatinine 3 0 0 0 0 1 (7)a 1 (2)
H e m o g l o b i n 3 0 1  ( 7 ) 0001  ( 2 )
Hyperglycemia 3 0 1 (7) 0 0 1 (2)
Neutropenia 3 0 0 1 (7)b 2 (14) 0 3 (5)
Thrombocytopenia 4 0 0 1 (7)b 001  ( 2 )
Proteinuria 3 0 0 0 1 (7) 1 (7)a 2 (4)
4 0 0001  ( 7 ) 1  ( 2 )
Prothrombin time 3 3 (23)c 1 (7)c 0001  ( 2 )
42  ( 1 5 ) c 00000
Values are expressed as n (%). aOne patient had grade 3 serum creatinine and grade 3 proteinuria. bOne patient with grade 3 neutropenia and 
grade 4 thrombocytopenia after the first 10-mg/kg dose was rechallenged at grade 1 neutropenia, without further decline after the second dose. 
cFour of six patients with grade 3 or 4 prothrombin time reported concomitant warfarin use, including the two patients with grade 4 prothrombin 
time.Arthritis Research & Therapy    Vol 10 No 5    Furie et al.
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49) on belimumab but not mycophenolate; however, the
effects were not consistent throughout the study.
At baseline, the median CD138+ plasmacytoid cell count and
percentage of lymphocytes in the placebo group and com-
bined group of patients treated with belimumab was 32 cells/
ml and 2.5%, respectively. The median change from baseline
in CD138+ plasmacytoid cells at day 84 for the single-dose
cohorts ranged from a 2.5% increase in the 1.0 mg/kg group
to a 1.5% decrease in the 10 mg/kg group. In contrast, a 4.5%
increase in CD138+ plasmacytoid cells was observed in the
placebo group. The overall treatment effect was statistically
significant in favor of belimumab for the single-dose cohorts
only (P = 0.0226).
Forty-four per cent of patients had elevations of anti-dsDNA
antibody concentrations (normal <10 IU/ml) at baseline; the
median baseline concentration of anti-dsDNA antibody was
22.0 IU/ml for patients treated with placebo and 27.5 IU/ml for
patients treated with belimumab. Overall, the percentage
change from baseline in anti-dsDNA antibody levels was not
significantly different for the single-dose or double-dose
cohorts compared with placebo. However, a subset analysis
of 31 belimumab-treated patients with anti-dsDNA antibody
levels 10 IU/ml or greater at baseline revealed significant
changes from 28 to 56 days after the last dose across all
cohorts (P < 0.05; Figure 3). Pair-wise comparison analyses
confirmed that changes in anti-dsDNA antibodies in the 20
mg/kg dose group were statistically different from placebo at
28, 42, and 56 days after the last dose (P < 0.01 for each
comparison). Of the three patients treated with belimumab
who had exceedingly high anti-dsDNA antibody values (>200
IU/ml) at baseline, two had a decrease in anti-dsDNA antibody
levels of more than 90% by the end of the study.
The percentage decrease in serum immunoglobulins tended
to be greater in patients treated with belimumab (maximal
median decrease over time for all doses combined was about
9% for IgG, about 11% for IgA, about 16% for IgM, and about
24% for IgE) compared with those treated with placebo; how-
ever, this trend did not achieve statistical significance. There
were three patients (20 mg/kg double dose) whose screening
and baseline IgG levels decreased from within the reference
range (680 to 1,445 mg/dl) to below the lower limit of normal
over 105 days (patient 1: 694 [baseline] to 527 [day 77] and
510 [day 105]; patient 2: 762 [baseline] to 651 [day 21] and
650 [day 105]; and patient 3: 809 [baseline] to 677 [day
105]). There were three patients (one receiving 4 mg/kg dou-
ble dose, one receiving 1 mg/kg single dose, and one in pla-
cebo) whose screening and baseline IgM levels (38 to 45 mg/
dl) decreased from within the normal reference range (33 to
248 mg/dl) to below (26 to 31 mg/dl) at different time points
between days 14 and 77. None of the patients with normal
screening and baseline IgA levels (70 to 407 mg/dl) dropped
to below the normal range. Those patients (n = 13) with IgE
levels above the reference range (>120 IU/ml) had a decline
of approximately 16% at days 77 and 84. None of the reduc-
tions in immunoglobulin isotypes were considered to be an AE
by the principal investigators. There were no significant
changes in C4 or C3 across treatment groups.
Clinical activity
The median baseline SELENA SLEDAI score for patients
treated with placebo was 4 (range 0 to 4), with 33% of
patients scoring 0. For patients treated with belimumab, the
median baseline SELENA SLEDAI score was 2 (range 0 to 8),
with 37% of patients scoring 0. Overall, there was a trend
toward reduced SELENA SLEDAI scores in both belimumab
and placebo groups. Changes in SELENA SLEDAI scores
over time stratified according to the baseline SELENA SLEDAI
score (≥ 4 or <4) for single- and double-doses are shown in
Figure 4. Analysis revealed that the subgroup of patients with
an SELENA SLEDAI score of 4 or greater had a median reduc-
tion of approximately 2 points 28 days after the last dose of
Figure 1
Belimumab concentrations Belimumab concentrations. (a) Concentrations in the single-dose 
cohort. (b) Concentrations in the double-dose cohort. Arrows indicate 
time of belimumab administration. Values are expressed as mean ± 
standard deviation.Available online http://arthritis-research.com/content/10/5/R109
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belimumab; however, this trend reversed over the next two vis-
its. The use of azathioprine or other immunosuppressive ther-
apy at baseline or whether a patient was ANA positive (ANA
≥1:40) or negative at baseline did not significantly influence
SELENA SLEDAI score responses in either belimumab or pla-
cebo groups (data not shown). Overall, there were no signifi-
cant differences between belimumab and placebo treatment
groups in SELENA SLEDAI scores or flare rates, as defined by
the SLE Flare Index.
The median baseline PGA scores, which ranged from 0.1 to
0.7 across all treatment groups in both cohorts, did not signif-
icantly change at any time point. Likewise, there were no sig-
nificant differences among treatment groups in either absolute
change or percentage change in any of the individual or com-
bined scales of the SF-36 Health Survey. In addition, analysis
of PGA and SF-36 Physical Component Score, stratified
according to the baseline SELENA SLEDAI score (≥4 or <4)
for single dose and double dose, did not reveal any significant
changes in these parameters over 84 and 105 days of the
study (Figures 5 and 6). The use of azathioprine or other immu-
nosuppressive therapy at baseline or whether a patient was
ANA positive (ANA ≥1:40) or negative at baseline did not sig-
nificantly influence PGA or SF-36 responses in either belimu-
mab or placebo groups (data not shown).
Discussion
B cells play a prominent role in the pathogenesis of SLE,
based on their ability to present antigen, secrete inflammatory
cytokines, and produce autoantibodies. Therefore, B-cell
depletion therapy for SLE has been an area of significant inter-
est. Several treatment strategies that directly or indirectly
affect B cells were recently investigated, including those that
target BLyS, CD20, CD22 and CD154, and BLyS receptors
[24,25].
CD40, a member of the TNF receptor superfamily, plays an
important role in T-cell-mediated B-cell activation. Cross-link-
ing of B-cell CD40 with CD154 (CD40 ligand), which is
expressed on T cells, induces B-cell proliferation [26]. Con-
centrations of soluble CD154 have been reported to be signif-
icantly higher in patients with SLE than in control patients [27].
Early studies in SLE murine models suggested that blocking
the interaction between CD40 and CD154 reduced nephritis
and anti-dsDNA antibodies, leading to improved survival [28-
30]. Furthermore, an anti-CD154 antibody, IDEC-131 (a
Table 5
Pharmacokinetics parameters by dose levels following single and double doses of belimumab
Pharmacokinetic 
parameter 
(mean ± SD)
Belimumab dose and number of patients per cohort
Cohort 1 (1.0 
mg/kg; n = 7)a
Cohort 2 (4.0 
mg/kg; n = 7)
Cohort 3 (10 
mg/kg; n = 7)
Cohort 4 (20 
mg/kg; n = 6)b
Cohort 5 (1.0 
mg/kg; n = 6)
Cohort 6 (4.0 
mg/kg; n = 7)
Cohort 7 (10 
mg/kg; n = 7)
Cohort 8 (20 
mg/kg; n = 6)
Cmax (μg/ml) 22.3 ± 4.2 81.2 ± 24.6 192.4 ± 34.9 523.9 ± 293.7 20.6 ± 3.0 105.4 ± 28.0 240.7 ± 41.7 368.1 ± 93.5
Cmax/dose (kg/
ml)
0.0223 ± 
0.0042
0.0203 ± 
0.0061
0.0192 ± 
0.0035
0.0262 ± 
0.0147
0.0206 ± 
0.0030
0.0264 ± 
0.0070
0.0241 ± 
0.0042
0.0184 ± 
0.0047
AUC0-∞ (day·μg/
ml)
156 ± 46 629 ± 258 1,510 ± 315 3,384 ± 1,424 148 ± 30 729 ± 145 1,849 ± 355 3,221 ± 781
AUC0-∞ /dose 
(day· kg/ml)
0.1561 ± 
0.0456
0.1572 ± 
0.0646
0.1510 ± 
0.0315
0.1692 ± 
0.0712
0.1477 ± 
0.0301
0.1822 ± 
0.0363
0.1849 ± 
0.0355
0.1611 ± 
0.0391
t1/2,α (day) 0.96 ± 0.61 1.49 ± 0.76 1.84 ± 0.89 1.27 ± 0.43 1.87 ± 0.99 1.23 ± 0.65 1.03 ± 0.48 2.21 ± 1.84
t1/2,β (day) 8.46 ± 2.21 9.88 ± 2.18 10.63 ± 2.89 11.34 ± 3.02 9.67 ± 1.33 9.91 ± 2.99 9.64 ± 2.20 14.13 ± 5.31
V1 (ml/kg) 44.90 ± 7.12 52.69 ± 
18.59
52.91 ± 
10.20
53.17 ± 40.89 48.95 ± 8.26 39.61 ± 
11.00
41.83 ± 7.63 56.60 ± 
15.02
Vss (ml/kg) 73.29 ± 
13.64
82.33 ± 
22.31
86.30 ± 
16.77
111.67 ± 
95.72
76.45 ± 
19.64
69.82 ± 
22.72
69.21 ± 
13.59
102.11 ± 
30.40
CL (ml/day per 
kg)
7.15 ± 3.18 7.20 ± 2.48 6.90 ± 1.57 7.33 ± 4.38 7.00 ± 1.38 5.68 ± 1.11 5.57 ± 1.02 6.52 ± 1.54
MRT (day) 11.13 ± 3.08 12.18 ± 3.22 13.03 ± 3.59 14.01 ± 4.17 10.97 ± 1.86 12.47 ± 4.07 12.65 ± 2.66 16.06 ± 4.15
Belimumab was given as a 2-hour infusion. Cohorts 1 to 4 received single doses of belimumab. Cohorts 5 to 8 received two doses of belimumab 21 
days apart. In the double dose cohorts, patients who missed doses or displayed positive immunogenicity were excluded. aOne patient in Cohort 1 was 
anti-belimumab antibody positive on days 14, 28, 56, and 84, and the data were, therefore, excluded from the mean calculation. bOne patient in Cohort 
4 did not receive a full dose secondary to urticarial reaction, and serum concentration data from this patient were excluded from the PK analysis. AUC0-
∞, area under the serum drug concentration-time curve from time 0 to infinite time; AUC0-∞ /dose, dose-normalized AUC0-∞ ; CL, clearance; Cmax, 
maximum serum drug concentration; Cmax/dose, dose-normalized Cmax; MRT, mean residence time; SD, standard deviation; t1/2,α, elimination half-life 
for the distribution phase; t1/2,β, elimination half-life for the terminal phase; V1, volume of distribution for the central compartment; Vss, volume of 
distribution at steady state.Arthritis Research & Therapy    Vol 10 No 5    Furie et al.
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humanized antibody that blocks CD40-CD154 interactions
[31]), was well tolerated in a phase II study conducted in 85
patients with mild-to-moderate SLE [32]; however, it failed to
meet the primary efficacy end-point, namely a reduction in
SLEDAI score at 20 weeks after six infusions of IDEC-131
ranging from 2.5 to 10 mg/kg. A short course of another anti-
CD154 antibody, BG9588, resulted in reductions in anti-
dsDNA antibodies, increased C3 concentrations, and
decreased hematuria in patients with proliferative lupus
nephritis, suggesting that the drug has an immunomodulatory
effect [33]. In a subset of this cohort, blockade of CD40 ligand
with BG9588 markedly increased the frequency of IgG-pro-
ducing B cells and IgG anti-DNA antibody producing B cells
in the peripheral blood of treated patients. Development of this
drug was suspended because of concerns about its prothrom-
botic effects [33].
Rituximab is a chimeric mouse-human mAb that is specific for
CD20 and is currently approved for the treatment of patients
with non-Hodgkin's B-cell lymphoma and patients with rheu-
matoid arthritis who have exhibited an inadequate response to
at least one TNF antagonist [34]. Several studies have investi-
gated rituximab in the treatment of SLE [35-38]. Recently, in
two dose-escalation studies of 48 patients with SLE, rituximab
therapy resulted in B-cell depletion and improved disease
activity [35,37]. Rituximab generally appeared to be safe,
although 12 out of 42 patients had documented human anti-
chimeric antibody responses [37,38]. Two studies [37,39]
have also demonstrated the safety of rituximab in the treatment
of patients with lupus nephritis. Similarly, epratuzumab, a
humanized anti-CD22 antibody, appeared to be safe in
patients with SLE and resulted in immediate decreases in B-
cell levels [40]. Antagonism of BLyS by TACI-Fc receptor or
AMG 623 (Fc-peptide fusion protein [peptibody] with binding
affinity for BLyS) has been evaluated in phase I SLE trials.
Gradual reductions in CD20 B cells and immunoglobulin iso-
types, particularly IgM, were observed [41,42].
Although anti-CD20 mAbs and BLyS antagonists both medi-
ate B-cell depletion, recent studies suggest that B-cells tar-
geted by anti-CD20 mAbs are not identical to those targeted
by BLyS antagonists [1,5,6]. CD20 is expressed on most B-
cell precursors in the bone marrow, immature B-cells, mature
naive B-cells and memory B-cells. In contrast, BLyS receptors
are not expressed on bone marrow B-cell precursors but are
expressed on immature and mature B-cells, memory cells, and
plasma cells. A recent study reported that a combination of
anti-CD20 mAbs and BLyS antagonists achieved more effec-
tive B-cell depletion in a murine model than either agent alone
[43]. Although treatment with agents such as rituximab results
in B-cell depletion and improved disease activity [35,38],
development of therapies that target other B-cell populations
(for example, belimumab) may play a crucial role in enhancing
B-cell depletion in patients with SLE. In addition, after treat-
ment with rituximab in SLE patients, BLyS levels significantly
increase after B-cell depletion until repopulation with B cells
occurs [25,44].
Figure 2
Changes in CD20+ B cells Changes in CD20+ B cells. Median percentage change from baseline 
in CD20+ B cells in (a) single-dose cohorts and (b) double-dose 
cohorts. Arrows indicate time of belimumab administration.
Figure 3
Change in anti-dsDNA antibodies Change in anti-dsDNA antibodies. Mean percentage change from 
baseline in 31 patients whose anti-dsDNA antibody levels were 10 IU/
ml or greater. dsDNA, double-stranded DNA.Available online http://arthritis-research.com/content/10/5/R109
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In animal models, BLyS has been shown to be essential not
only to the survival of B cells but also to the survival of plasma
cells [45]. Belimumab inhibits soluble BLyS activity at subna-
nomolar concentrations in a murine model [19]. Belimumab,
administered to monkeys at 5, 15, or 50 mg/kg doses every
other week, affected peripheral B cells and lymphoid tissues
as early as 3 months and 1 month, respectively [20]. Maximum
reductions of up to 75% in CD20+ B cells and CD21+ plasma-
cytoid cells occurred at 13 to 26 weeks [20]. These effects
were believed to be related to apoptosis induced by pro-
longed BLyS depletion and were reversible within 5 months of
drug withdrawal.
The pharmacokinetic profile of one or two doses of belimumab
was dose proportional and consistent with a fully human mAb.
A half-life of 14 days supports dosing every 28 days in future
long-term trials. A significantly greater reduction (up to 47%
reduction) in the median percentage of CD20+ B cells was
observed in patients treated with one or two doses of belimu-
mab compared with placebo. This is consistent with the ability
of belimumab to inhibit BLyS biologic activity. Significant
reductions in anti-dsDNA antibody were observed 28 to 56
days after the last dose in the subset of patients with levels of
10 IU/ml or greater at baseline. Immunoglobulin levels, partic-
ularly IgM and IgE, were reduced in some belimumab cohorts
compared with placebo.
SELENA SLEDAI scores, PGA, SLE Flare Index, and SF-36
Physical Component Score did not significantly improve in this
study population. The reasons for this relate to the limited
number (one or two) of belimumab infusions, the short dura-
tion of the study, the relatively small numbers of patients, and
the inclusion of patients with limited or no disease activity
(33% had no disease activity at baseline). However, the dem-
onstrated biologic activity suggests that long-term treatment
may produce a clinical response and therapeutic benefit in
Figure 4
SELENA SLEDAI scores SELENA SLEDAI scores. The SELENA SLEDAI scores in the single-dose and double-dose cohorts over time are presented, stratified by baseline 
SELENA SLEDAI score (≥4 or <4). Values are expressed as mean ± standard error. SELENA, Safety of Estrogens in Lupus Erythematosus National 
Assessment; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.Arthritis Research & Therapy    Vol 10 No 5    Furie et al.
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patients with SLE. If the effects of belimumab in humans are
comparable to those in monkeys, then we estimate that the
depletion of CD20+ B cells and CD21+ plasmacytoid cells will
be 50% to 80% within 3 to 6 months of continuous therapy.
Significant reduction in B cells was observed in the lymphoid
tissue of monkeys after 1 month of treatment but not observed
in the peripheral blood until 2 months of continuous therapy
[20]. Hence, clinical effects might be delayed until there is a
sustained reduction in key B-cell populations. In a phase II SLE
study of 449 SLE patients with baseline SELENA SLEDAI
scores of 4 or greater (average SELENA SLEDAI score 9.6)
treated with 1, 4, and 10 mg/kg belimumab or placebo plus
standard of care SLE therapy, significant improvement in sero-
logically active (ANA ≥1:80 and/or anti-dsDNA ≥30 IU/ml)
[46] SLE patients in combined belimumab dose groups com-
pared with placebo was seen at week 4 for PGA, week 12 for
SF-36, and week 52 for SELENA SLEDAI score [47,48].
The results of this study demonstrate that treatment with one
or two intravenous doses of belimumab is safe and well toler-
ated in patients with mild to moderate SLE. The AE profile of
belimumab was comparable to that of placebo, and no serious
AEs were deemed related to study agent. Only one patient
experienced an infusion reaction, and this reaction responded
to treatment with antihistamines. In addition, only one patient
developed neutralizing antibodies to belimumab. Because
belimumab is a fully human mAb, it is expected that patients
are less likely to develop immune responses and hypersensi-
tivity reactions.
Conclusion
This study demonstrated that belimumab was biologically
active in vivo and was safely administered to patients with
SLE. These findings supported the initiation of phase II studies
investigating the safety and clinical activity of belimumab in
patients with SLE and rheumatoid arthritis.
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